| Online-Ressource |
Verfasst von: | Möckel, Martin [VerfasserIn]  |
| Slagman, Anna [VerfasserIn]  |
| Vollert, Jörn Ole [VerfasserIn]  |
| Ebmeyer, Stefan [VerfasserIn]  |
| Wiemer, Jan C. [VerfasserIn]  |
| Searle, Julia [VerfasserIn]  |
| Giannitsis, Evangelos [VerfasserIn]  |
| Kellum, John A. [VerfasserIn]  |
| Maisel, Alan [VerfasserIn]  |
Titel: | Rationale and design of the IMPACT EU-trial |
Titelzusatz: | improve management of heart failure with procalcitonin biomarkers in cardiology (BIC)-18 |
Verf.angabe: | Martin Möckel, Anna Slagman, Jörn Ole Vollert, Stefan Ebmeyer, Jan C. Wiemer, Julia Searle, Evangelos Giannitsis, John A. Kellum, Alan Maisel |
E-Jahr: | 2018 |
Jahr: | 8 January 2018 |
Umfang: | 7 S. |
Fussnoten: | Gesehen am 05.05.2020 |
Titel Quelle: | Enthalten in: Biomarkers |
Ort Quelle: | London : Taylor & Francis, 1996 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 23(2018), 1, Seite 97-103 |
ISSN Quelle: | 1366-5804 |
Abstract: | OBJECTIVES: To evaluate the effectiveness of procalcitonin (PCT)-guided antibiotic treatment compared to current treatment practice to reduce 90-day all-cause mortality in emergency patients with shortness of breath (SOB) and suspected acute heart failure (AHF). - BACKGROUND: Concomitant AHF and lower respiratory tract (or other bacterial) infection in emergency patients with dyspnea are common and can be difficult to diagnose. Early and adequate initiation of antibiotic therapy (ABX) significantly improves patient outcome, but superfluous prescription of ABX maybe harmful. - METHODS: In a multicentre, prospective, randomized, controlled process trial with an open intervention, adult emergency patients with SOB and increased levels of natriuretic peptides will be randomized to either a standard care group or a PCT-guided group with respect to the initiation of antibiotic treatment. In the PCT-guided group, the initiation of antibiotic therapy is based on the results of acute PCT measurements at admission, using a cut-off of 0.2 ng/ml. A two-stage sample-size adaptive design is used; an interim analysis was done after completion of 50% of patients and the final sample size remained unchanged. Primary endpoint is 90-day all-cause mortality. - CONCLUSIONS: The current study will provide evidence, whether the routine use of PCT in patients with suspected AHF improves outcome. |
DOI: | doi:10.1080/1354750X.2017.1420823 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1080/1354750X.2017.1420823 |
| DOI: https://doi.org/10.1080/1354750X.2017.1420823 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Acute heart failure |
| Adult |
| Anti-Bacterial Agents |
| antibiotic therapy |
| Bacterial Infections |
| Biomarkers |
| Calcitonin |
| Dyspnea |
| Emergency Service, Hospital |
| Female |
| Heart Failure |
| Humans |
| Male |
| Outcome Assessment, Health Care |
| procalcitonin |
| Proportional Hazards Models |
| Prospective Studies |
| Research Design |
K10plus-PPN: | 1697203701 |
Verknüpfungen: | → Zeitschrift |
Rationale and design of the IMPACT EU-trial / Möckel, Martin [VerfasserIn]; 8 January 2018 (Online-Ressource)